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Abstract
In the era of combined antiretroviral therapy, HIV-1 infected individuals are living longer lives; however, longevity is met with an
increasing number of HIV-1 associated neurocognitive disorders (HAND) diagnoses. The transactivator of transcription (Tat) is
known to mediate the neurotoxic effects in HAND by acting directly on neurons and also indirectly via its actions on glia. The
Go/No-Go (GNG) task was used to examine HAND in the Tat transgenic mouse model. The GNG task involves subjects
discriminating between two stimuli sets in order to determine whether or not to inhibit a previously trained response. Data reveal
inhibitory control deficits in female Tat(+) mice (p = .048) and an upregulation of cannabinoid type 1 receptors (CB1R) in the
infralimbic (IL) cortex in the same female Tat(+) group (p < .05). A significant negative correlation was noted between inhibitory
control and IL CB1R expression (r = −.543, p = .045), with CB1R expression predicting 30% of the variance of inhibitory control
(R2 = .295, p = .045). Furthermore, there was a significant increase in spontaneous excitatory postsynaptic current (sEPSC)
frequencies in Tat(+) compared to Tat(−) mice (p = .008, across sexes). The increase in sEPSC frequency was significantly
attenuated by bath application of PF3845, a fatty acid amide hydrolase (FAAH) enzyme inhibitor (p < .001). Overall, the GNG
task is a viable measure to assess inhibitory control deficits in Tat transgenic mice and results suggest a potential therapeutic
treatment for the observed deficits with drugs which modulate endocannabinoid enzyme activity.
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Introduction
The World Health Organization estimates 36.7 million people
are diagnosed with human immunodeficiency virus type 1
(HIV-1) worldwide, which has been considered a fatal diag-
nosis before antiretroviral treatments were established. With
the advent of combined antiretroviral therapy (cART), HIV-1
infection has become a chronic but manageable condition with
decreased mortality rates and increased life expectancies
(Harrison et al. 2010). Before cART, the later stages in the
progression of HIV-1 infection were marked with HIV-1 as-
sociated dementia (HAD), but a newer, milder form of cogni-
tive impairment has emerged during the post-cART era called
HIV-1-associated neurocognitive disorders (HAND) (Ellis
et al. 2007). Symptoms that have been associated with
HAND in the post-cART era include reduced mental acuity,
and deficits in working memory, attention, and inhibitory con-
trol (Connolly et al. 2014; Ernst et al. 2003; Wang et al. 2017)
that are specifically associated with cortical brain structures
such as the prefrontal cortex (PFC) (Heaton et al. 2011).
It is unclear how HANDmanifests and what molecular and
cellular mechanisms are driving HAND, however the severity
of synaptic disruption and dendritic injury is correlated with
the severity of expressed symptoms of HAND (Everall et al.
1999; Masliah et al. 1997). As the virus itself does not directly
infect neurons, neuronal damage and synaptodendritic injury
occurs indirectly through the release of toxic substances from
infected microglia and other non-neuronal cells in the central
nervous system (CNS), including viral proteins, cytokines/
chemokines, and free radicals. Among the viral proteins, the
transactivator of transcription (Tat) in particular plays a key
role in HAND pathogenesis as Tat continues to be detected in
the HIV-1 infected brain despite cART (Johnson et al. 2013;
Mediouni et al. 2012). Further, expression of the Tat protein in
transgenic animal models, without the presence of the virus
itself or other viral proteins, tend to mirror the neuropathology
and cognitive deficits observed in HIV-1 patients with HAND
(Bruce-Keller et al. 2008; Carey et al. 2012; Fitting et al. 2010;
Hauser et al. 2009; Kesby et al. 2014; Kesby et al. 2015;
Marks et al. 2016; Maung et al. 2014; Mediouni et al. 2015;
Paris et al. 2014a; Paris et al. 2014c; Toggas et al. 1994). Tat
exerts its effects via multiple mechanisms, including direct
and indirect effects on neurons (Chen et al. 1997; Cheng
et al. 1998; El-Hage et al. 2008; El-Hage et al. 2005; Kutsch
et al. 2000; Lipton 1993; Liu et al. 2000; Magnuson et al.
1995; Nath 2002). Tat can depolarize neurons directly by
interacting with a variety of surface receptors, such as
NMDA receptors (Eugenin et al. 2007; Longordo et al.
2006; Raybuck et al. 2017), and potentiate glutamate-
induced excitotoxicity (Longordo et al. 2006), leading to in-
creases in [Ca2+]i, and dendritic structural and functional de-
fects in neurons (Fitting et al. 2014; Green et al. 2018;
Haughey et al. 1999; Mattson et al. 2005). Additionally, Tat
can induce neurotoxicity through indirect mechanisms via its
actions on microglia and astrocytes by stimulating the produc-
tion of proinflammatory cytokines (Chen et al. 1997), induc-
ing TNF-α and IL-1 in monocytes and macrophages and a
milieu of cytokines and chemokines in astrocytes, including
IL-8, RANTES, MCP-1, and TNF-α (El-Hage et al. 2005;
Kutsch et al. 2000).
One avenue for treating the effects of HIV-1 Tat in the brain
is the modulation of the endocannabinoid (eCB) system.
Modulating function of endogenous cannabinoids emerges
as a promising therapeutic target in several neurodegenerative
diseases due to their anti-excitotoxic and anti-inflammatory
proper t ies (Per twee 2014; Scot te r e t a l . 2010) .
Endocannabinoids have been reported to be up-regulated in
disorders, such as Parkinson’s disease and Alzheimer’s dis-
ease, and reduce or abolish unwanted effects of these disorders
or slow their progression (Pertwee 2014; Scotter et al. 2010).
Interestingly, an upregulation of expression of cannabinoid
type 1 and type 2 receptor levels (CB1R and CB2R, respec-
tively) has been demonstrated in the CNS of HIV-1-infected
individuals (Cosenza-Nashat et al. 2011) and in simian immu-
nodeficiency virus (SIV) encephalitis (Benito et al. 2005).
There is support for existing cannabinoid signaling pathways
that can decrease neuronal injury, including CB1R activation
as well as inhibition of NMDAR-mediated calcium influx
(Liu et al. 2009). Multiple studies have indicated that CB1R
stimulation limits synaptic excitation mediated by glutamate
with CB1R activation decreasing glutamate-mediated excit-
atory postsynaptic currents (EPSCs) (Andre et al. 2010;
Chevaleyre et al. 2006; Harkany et al. 2008; Marsicano et al.
2003; Monory et al. 2006; Rossi et al. 2011). Nevertheless,
therapeutic use of direct CB1R agonists is limited due to the
pervasive psychoactive side effects associated with CB1R ag-
onists that include sensorimotor, affective and cognitive dis-
turbances (Di Marzo 2008). Thus, research efforts have fo-
cused on development of drugs targeting components of the
endogenous cannabinoid system, including enzymes regulat-
ing the biosynthesis and degradation of the two major endog-
enous cannabinoids N-arachidonoylethanolamine (ananda-
mide/AEA) and 2-arachidonoylglycerol (2-AG) (Ahn et al.
2008; Lichtman et al. 2010; Petrosino and Di Marzo 2010).
There is strong preclinical evidence that selective inhibitors of
the main AEA-metabolizing enzyme, fatty acid amide hydro-
lase (FAAH), can ameliorate the unwanted effects in a variety
of different laboratory animal models of neurodegenerative
diseases (Naidoo et al. 2011; Pertwee 2014). The new gener-
ation of hydrolytic enzyme inhibitors, such as the FAAH en-
zyme inhibitor PF3845, has demonstrated highly improved
selectivity, potency and produce less side effects compared
to previously available compounds (Ahn et al. 2009; Booker
et al. 2012; Ignatowska-Jankowska et al. 2015; Ignatowska-
Jankowska et al. 2014; Niphakis et al. 2013; Parker et al.
2015). In a recent in vitro study we have demonstrated that
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PF3845 is protective against HIV-1 Tat-induced excitotoxicity
and neuronal injury by involving CB1R and CB2R-mediated
mechanisms (Hermes et al. 2018; Xu et al. 2017).
The aim of the present study was (1) to determine the ef-
fects of Tat on inhibitory control by using the PFC-related
operant conditioning Go/No-Go (GNG) task, (2) to assess
the effects of Tat on the eCB system by quantifying the chang-
es in CB1R expression in the medial PFC (mPFC) using im-
munohistochemistry, and (3) to investigate the potential neu-
roprotective effects of the FAAH enzyme inhibitor PF3845 on
Tat-induced increases in glutamatergic neurotransmission
ex vivo. Results revealed inhibitory control deficits in female
Tat(+) mice that also demonstrated an upregulation of CB1R
expression in the infralimbic cortex (IL). A significant nega-
tive correlation between inhibitory control and IL CB1R ex-
pression demonstrated that deficits in inhibitory control were
associated with an upregulation of IL CB1R expression, with
IL CB1R expression predicting 30% of the variance of inhib-
itory control. Further, Tat-induced increases in spontaneous
excitatory postsynaptic current (sEPSC) frequencies (females
and males) were attenuated by application of PF3845, indicat-




Doxycycline (DOX)-inducible, brain-specific HIV-1IIIB Tat1–
86 transgenic mice were developed on a C57BL/6J hybrid
background as described in detail in previous literature
(Bruce-Keller et al. 2008; Hahn et al. 2015b). Tat expression,
which is under the control of a tetracycline-responsive pro-
moter controlled by glial fibrillary acidic protein (GFAP) ex-
pression, was induced with a specially formulated chow con-
taining 6 mg/g DOX (product TD.09282; Harlan,
Indianapolis, IN). Inducible Tat(+) transgenic mice express
both GFAP-rtTA and TRE-tat genes, while control Tat(−)
transgenic mice express only the GFAP-rtTA genes. At
~4 weeks of age transgenic mice were genotyped to confirm
the presence of Tat and/or rtTA transgenes.
In all experiments animals were counterbalanced for sex
within groups. For the behavioral and immunohistochemistry
studies, adult transgenic mice (8 weeks of age) were experi-
mental naive and included 7 Tat(+) mice (4 female) and 7
Tat(−) mice (3 female). To induce the Tat protein animals were
fed DOX at ~6 weeks of age and kept on this diet until
sacrificed for immunohistochemistry experiments (more than
10 months of DOX treatment). For the western blot and elec-
trophysiology studies a new set of adult Tat transgenic mice
[Tat(−) and Tat(+), DOX exposure for more than 5months and
at least ~1 month, respectively] was used with at least 6–8
mice in each group (3–4 females/per group). All animals were
bred by the University of North Carolina Division of
Comparative Medicine (UNC DCM) and individually housed
(starting at 6 weeks of age) under a 12/12 h light-dark (LD)
cycle. The colony room temperature was maintained at 21 °C
and 32% humidity. All animal procedures were approved by
the University of North Carolina Institutional Animal Care
and Use Committee (IACUC) and are in keeping with
AAALAC guidelines.
Apparatus
Standard mouse experimental chambers (MED Associates
ENV-307 W) were housed in sound and light attenuating cu-
bicles (MED Associates ENV-022MD). Each chamber was
equipped with a curved five nose-poke wall (MED
Associates ENV-115C) where subjects performed their re-
sponses. Each nose-poke contained an imbedded yellow
LED to illuminate the port. A 28 V DC, 100 mA house light
(MED Associates ENV-215 W) was mounted on the wall
opposite of the curved five nose-poke wall and illuminated
the chamber during each session. Sucrose pellets (BioServ
Product# F06233 - Dustless Precision Pellets®) weighing
20 mg served as reinforcers and were delivered via a pellet
dispenser (MED Associates ENV-203-20) into a receptacle
(MED Associates ENV-303 W), which was illuminated by a
receptacle light (MED Associates ENV-303RL). The pellet
receptacle was located under the house light, opposite of the
curved nose-poke wall. Behavioral testing occurred in a dark
room illuminated by red fluorescent lighting. The testing room
was kept at 22 °C room temperature with 30% humidity.
Behavioral Training
Training took place over four phases adapted from procedures
described in previous literature (Gubner et al. 2010; Loos et al.
2010): shaping the nose-poke response, shaping the go re-
sponse, titrating the limited hold (LH), and testing. Unless
otherwise stated, advancement from a phase was contingent
on criteria requiring the subject to earn 40 reinforcers and
maintain 80% accuracy on 2 consecutive days. Subjects ad-
vanced through the phases individually as they independently
reached criteria. This advancement style ensured that all sub-
jects received the same relative training and prevented
overtraining. Additionally, the intertrial interval (ITI) used in
all phases was 10 s. The house light was illuminated 1 s before
the start of the trial and was terminated once the animal re-
trieved a reinforcer. All sessions terminated after 30 min or
after 100 reinforcers were earned.
After individual housing placement, mice were allowed to
acclimate to their new living conditions for one week and on
the final two days, weights were taken and averaged to com-
pute the initial weights from which the 85% target weight
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could be derived. At ~7 weeks of age, mice were gradually
transitioned from ad libitum feeding to a restricted diet to
lower their body weights to 85% of initial. At ~8 weeks of
age mice entered the study and underwent 3 training phases
(please see supplemental material for full description of the 3
training phases). Briefly, phase 1 started with magazine train-
ing in which a pellet was dispensed on a variable-time 2 min
schedule to train the animal where reinforcement was deliv-
ered and familiarized them with the sound of a pellet being
dispensed. Once subjects met criteria for this phase, they ad-
vanced to phase 2 where subjects were introduced to the chain
of behaviors necessary to receive reinforcement on a Go trial
on 80% of trials and the No-Go trial on 20% of trials. On a Go
trial first the subject was required to make a single poke into a
specified port to receive reinforcement. On a No-Go trial, the
house light flashing served as the No-Go stimulus and re-
quired the subject to not poke into any ports to receive rein-
forcement. Once subjects met criteria for this phase, they ad-
vanced to phase 3, which proceeded exactly as phase 2 but
collected the go reaction time (GoRT), which was the latency
from when the Go stimulus illuminated to when the subject
performed a nosepoke into that port. Here an individually
titrated LH was introduced on the Go and No-Go stimuli,
which required the subject to respond to the Go stimulus, or
withhold a response in the presence of the No-Go stimulus, in
the LH period equal to the 90th percentile of their GoRT in
order to receive reinforcement. By adding the individually
titrated LH, we were able to record omissions to the Go stim-
ulus, which was a necessary measure for calculating an index
of inhibition. Subjects that met criteria for this phase advanced
to the testing phase 4.
Phase 4 was the testing phase and occurred 10 months after
DOX treatment. Trials presented during phase 4 are summa-
rized in Fig. 1. The setup for this phase was the same as phase
3 with the exception that the No-Go trials were increased to
50% of the trials. During this phase, PInhibition was calculated
from the number of omitted Go and No-Go trials. The formula
is summarized below. The product of this formula is bound
between 1 and − 1 where numbers closer to −1 indicate
more inhibition on Go trials, numbers closer to 1 indicate
more inhibition on No-Go trials, and numbers around 0
indicate a lack of discrimination between Go and No-Go
trials. Test phase takes place on a single day and subjects
were removed from the study once they complete their test
phase.
PInhibition ¼ PNo−go−POmission1−POmission
Note that PNo-Go indicates the proportion of correct omis-
sions during No-Go trials to the total number of No-Go trials,
whereas POmission indicates the proportion of incorrect
omissions during Go trials to the total number of Go trials.
Values closer to 0 indicate lower omissions than values closer
to 1.
In addition to the PInhibition, PNo-Go, and POmission scores,
perseverative and premature responses were tracked as indices
of hyperactivity. A perseverative response was counted as any
responses made into the Start stimulus after the initial re-
sponse requirement is met. The total number of perseverative
responses made on either trial type was combined and com-
pared between subjects. A premature response was counted
when the subject made a response into the Start or Go stimulus
before that stimulus was illuminated. The total number of
premature responses on either stimulus were combined and
compared between subjects. Traditionally, premature
responding has been a measure of impulsivity; however, stud-
ies interpreting this measure as impulsivity used timeouts in
conjunction with a premature response. The task used here did
not include timeouts, thus premature responses lacked a con-
sequence and could not be interpreted as impulsivity. Finally,
reinforcers earned and accuracy measurements on Go trials
served as an index for motivation to earn reinforcers and abil-
ity to perform the basic trained operant response reliably.
Immunohistochemistry
At the conclusion of behavioral testing, Tat transgenic mice
were anesthetized with isoflurane and perfused using a 4%
paraformaldehyde solution. Brains were extracted and post-
fixed in 4% paraformaldehyde for 6 h at 4 °C before being
washed 3x for 1 h at room temperature in 1x phosphate buffer
solution (PBS) and incubated for 24 h at 4 °C in a 20% sucrose
solution. Brains were then encapsulated in Tissue-Tek O.C.T
compound before being frozen and kept at −80 °C until sec-
tioning. Coronal sections were cut using a Leica CM3000
cryostat (Leica, Deerfield, IL) at −21 ± 1 °C to a width of
30 μm thickness. Sections were washed, and then treated with
a permeability solution [0.1% Triton 100x, 0.1% bovine se-
rum albumin (BSA) in PBS] for 15 min. Following, tissue
sections were washed again before being exposed to a
blocking solution (1% normal goat serum, 0.2% BSA in
PBS) for 1 h. Sections were then incubated overnight at
4 °C in primary antibodies diluted in blocking solution against
MAP2ab (mouse, Millipore, MAB378; 1:1000) and the rat
CB1R-NH (raised to amino acids 1–77 of the N-terminus;
rabbit; 1:500, Tsou et al. 1998). Next day, sections were
washed again before being exposed to secondary antibodies
conjugated to goat-anti-mouse Alexa 488 (Molecular Probes,
O-6380, 1:500, green) forMAP2ab and goat-anti-rabbit Alexa
594 (Molecular Probes, A11012; 1:1000, red) for CB1R-NH.
Secondary antibodies were diluted in the blocking solution
previously described and applied for 1 h at room temperature.
Following secondary application, tissue sections were washed
in PBS and exposed to Hoechst (Hoechst 33342; Molecular
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Probes, H3570) for 3 min. Tissue sections were then washed
and mounted on SuperFrost Plus Slides (Fisher Scientific,
Pittsburgh, PA) using ProLong Gold antifade mounting media
(Molecular Probes, P36930).
For imaging, eight tissue sections were chosen per animal
that were representative of progression through the mPFC as
per the Allen Mouse Brain Atlas (2004). Confocal immuno-
fluorescent images for CB1R expression were gathered by an
experimenter blinded to genotype and sex using a Zeiss
LSM800 T-PMT laser scanning confocal microscope (Zeiss,
Thornwood, NY) fitted with a 63x oil immersion objective.
Images were acquired by using identical parameters for all
groups (i.e., identical objective, zoom, laser intensity, gain,
offset, and scan speed) optimized for control tissues. ZEN
2010 blue edition software (Carl Zeiss, Inc., Thornwood,
NY) was used to collect the images. Four images were taken
per tissue section (2 images from the left and 2 images from
the right hemisphere), with unique fields of view for each
section, one from the prelimbic (PL) and one from the
infralimbic (IL) region of each hemisphere. The entire image
was used as region of interest and processed using ImageJ
(Schneider et al. 2012) to quantify the density of CB1R-NH
staining per pixel in each image. Mean fluorescent intensities
were determined with ImageJ without digital manipulation.
For each animal, in each brain region (PL and IL), data are
averaged across sections.
Western Blot Analysis
Western blot analysis was carried out as previously described
(Xu et al. 2017). In brief, tissue from the mPFC of Tat trans-
genic mice (DOX exposure for more than 5 months) was
Fig. 1 Demonstrates one of two trial arrangements of the Go/No-Go task
at the testing phase that were used in this experiment. A trial begins with
the Start stimulus being illuminated and the subject is required to make a
response into the Start stimulus to begin the trial. On Go trials, the subject
is required to wait for a 2 s inter-stimulus interval (ISI) before the Go
stimulus will be presented. For both Go and No-Go arrangements, re-
sponses made into the Start stimulus during this time are counted as
preservative responses and responses into the Go stimulus are counted
as premature responses. Once the Go stimulus illuminates, the subject has
until its individually titrated limited hold period lapses to make a response
before that trial is scored as an incorrect omission. If the subject
responded correctly, it receives a reward and waits for a 10 s intertrial
interval (ITI) before a new trial begins. An incorrect omission yields no
reward and the subject must wait for the 10 s ITI before a new trial
commences. The No-Go trials proceeded very similarly, except during
the 2 s ISI seen in Go trials a flashing house light is presented. After 2 s,
the Go stimulus is illuminated and the house light continues to flash. The
subject has until its individually titrated limited hold period lapses to
make an incorrect response or the trial is counted as a correct omission.
If the subject correctly omitted a response, it receives a reward before
waiting for the 10 s ITI to start a new trial; otherwise, the subject simply
waits for the 10 s ITI with no reward. Taken together, this setup presents a
conditional discrimination in which the subject is required to alter
responding depending on the status of the house light. For the other trial
arrangements, the role of the house light is simply reversed where now a
flashing house light indicates the subject should perform a response for
reinforcement. These two arrangements are counterbalanced between
groups and sexes to account for any fear inducing qualities of the flashing
house light. There were no statistically significant differences between the
two arrangements on any measure (all p’s > .05)
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freshly harvested and homogenized on ice in an appropriate
volume of ice-cold RIPA Lysis and Extraction buffer (G-
Bioscience) with protease inhibitor cocktail (Amresco,
Ohio). Blots were incubated with anti-CB1R (rabbit polyclon-
al; Cayman; 1:1000 dilution for 3 h), and anti β-Actin (anti-
mouse from Cell Signaling; 1:1000 for 3 h) at room tempera-
ture. ECL reaction (Amersham) was used to dectect immuno-
reactive bands from the blot using BioRad Gel Doc XR+
system and image acquiring software (Image Lab ver. 5.1).
Densitometric analysis used a modified version (version
1.59) of the Scion Image software (Scion Corporation).
Electrophysiology
For the electrophysiology experiments brain slices of Tat
transgenic mice (DOX exposure for at least ~1 month) were
prepared following an established procedure as previously
described (Xu et al. 2016). Mice were anesthetized with
isofluorane and brains were removed after decapitation and
submerged into ice-cold sucrose cutting solution containing
in mM: 254 sucrose, 10 D-glucose, 26 NaHCO3, 2 CaCl2, 2
MgSO4, 3 KCl, and 1.25 NaH2PO4, saturated with 95% O2/
5% CO2, at pH 7.4, 300 mOsm. Coronal brain slices (300 μm
thickness) containing the mPFC were obtained using the VT
1000S microtome (Leica, Deerfield, IL). Slices were then in-
cubated at 32 ± 1 °C for 30 min in artificial cerebrospinal fluid
(aCSF) and maintained at room temperature for at least an
additional 30 min before start of the experiment. At the start
of the experiment slices were transferred to a submersion
chamber (Warner Instruments, Hamden, CT) on a Siskiyou
4080P fixed-stage system (Grants Pass, OR) with a continu-
ous flow rate of 2–3 mL/min aCSF saturated with 95%O2/5%
CO2 at 32 ± 1 °C using an inline heater (Warner SC-20,
Hamden, CT). Slices were visualized using an Axio
Examiner A1 microscope (Zeiss, Thornwood, NY) equipped
with a 40x water-immersion objective coupled with an infra-
red differential interference contrast and an integrated Dodt
gradient camera system. Recordings were taken from mPFC
pyramidal neurons of layer 2/3, including the PL and IL re-
gions, and were identified as being approximately 50–250 μm
from the slice midline and possessing a pyramidal neuron
morphology. Patch recording pipettes with ~5 MΩ resistance
were fabricated using a PC-10 puller (Narishige, Greencale,
NY). For the whole-cell patch-clamp recordings the intracel-
lular recording solution contained in mM unless otherwise
stated: 115 K-gluconate, 10 HEPES, 5 KCl, 2 MgCl2, 2 Mg-
ATP, 2 Na2-ATP, 0.4 Na2GTP and 10 Na2-phosphocreatine
(pH 7.33). Recordings from mPFC neurons were amplified
and filtered at 2 kHz (MultiClamp 700B amplifier, Axon
Instruments, Union City, CA), and digitized with a sampling
rate of 10 kHz (Digidata 1550A, Axon Instruments).
Spontaneous currents were recorded at resting membrane po-
tential (~75 ± 5 mV). Therefore, inward currents are
considered excitatory amino acid currents (EPSCs), whereas
the outward currents (inhibitory postsynaptic currents, IPSCs)
were blocked by bath application of bicuculline (10 μM).
Drugs, such as PF3845 (1 μM) were administered by bath
application and synaptic currents were collected for 5 min
for each experimental condition. Access resistance (<25
MΩ) was regularly monitored during recordings, and cells
were rejected if resistance changed >15% during the experi-
ment. Off-line analysis of synaptic currents was performed
using the Minianalysis software (Version 6.0.8; Synaptosoft,
Decatur, GA). Data for PF3845 conditions are presented as
PF3845-induced change (Δ) on sEPSC frequency and sEPSC
amplitude, indicating percent inhibition from control (control
is set to 0%). Quantitative analyses were performed on 14–26
neurons per group.
Statistical Analysis
All descriptive statistics are reported as means (M) ± standard
error of the mean (SEM). All statistical analyses were conduct-
ed using one-way or two-way analysis of variances
(ANOVAs) with Sex (2 levels: male, female) and/or
Genotype [2 levels: Tat(−), Tat(+)] as factors, followed by
Tukey’s post hoc tests if necessary. An alpha level of p < .05
was considered significant for all statistical tests used.
Additionally, for the PF3845-induced inhibition data on
sEPSCs a one-sample t-test was conducted to determine
whether PF3845 significantly inhibited currents from percent
control. When analyzing each group separately multiple com-
parisons were controlled for by dividing the alpha level by the
number of comparisons. The relationship between inhibitory
control and CB1R expression was assessed by Pearson corre-
lation and simple linear regression analyses. Simple linear
regression analysis was conducted to determine if observed
changes in CB1R expression was significantly predictive of
the behavioral measure inhibitory control. Effect sizes are re-
ported using ω2 to best represent population effect size using
an unbiased estimate (Yiğit and Mendes 2018).
Results
Behavioral Testing
Results from behavioral testing are summarized in Fig. 2. A
two-way ANOVA revealed a significant interaction between
Sex and Genotype on PInhibition, F (1, 10) = 6.61, p = .028,
ω2 = .27 (Fig. 2a). Specifically female Tat(+) mice (M = .06,
SEM = .05) demonstrated poorer inhibitory control than male
Tat(+) mice (M = .72, SEM = .12; p = .048). There was no sig-
nificant main effect of Sex or Genotype on PInhibition (all p’-
s > .05). When considering the results for PInhibition, it is im-
portant to remember that this score derives from inhibition on
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both Go and No-Go trials and that a low score can stem from
suppression of operantly trained behavior on Go trials, as
recorded by POmmision, or from a lack of inhibition on No-
Go trials, as recorded by PNo-Go. When considering scores
Fig. 2 Details results from the Go/No-Go operant task. In all panels, data
is organized, from left to right, as male Tat(−), male Tat(+), female Tat(−),
and female Tat(+). (a) PInhibition indicates the probability that a subject will
correctly inhibit its behavior when signaled (No-Go trials) while remain-
ing sensitive to incorrect omissions (Go trials) and is obtained through the
formula: PInhibition = (PNo-Go-POmission)/(1- POmission). Using this calcula-
tion, PInhibition provides data on inhibitory control, or the ability of the
subject only to omit responses when appropriate. When PInhibition = 1, the
subject performed perfectly and only omitted responses during the No-Go
trials; when PInhibition = 0, the subject either did not omit any responses or
omitted every response. Data demonstrate a significant Sex by Genotype
interaction on inhibitory control (#p = .028) with female Tat(+) mice
showing poorer inhibitory control compared to male Tat(+) subjects
[*p = .048 vs. male Tat(+)]. (b) POmission indicates the proportion of in-
correct omissions during go trials to the total number of go trials. Values
closer to 0 indicate lower incorrect omissions than values closer to 1. Data
demonstrate that subjects in all groups show a low likelihood that they
will incorrectly inhibit a nosepoke on a go trial. No significant differences
were noted between groups. (c) PNo-Go indicates the proportion of correct
omissions during no-go trials to the total number of no-go trials. Values
indicate the likelihood that a subject will correctly omit a response on a
no-go trial with values closer to 0 indicating a lesser likelihood than
values closer to 1. A significant Sex by Genotype interaction was noted
on PNo-Go (
#p = .038) with female Tat(+) mice showing less correct omis-
sions on No-Go trials compared to male Tat(+) subjects. (d) Perseverative
responses across both trial types. Perseverative responses are nosepokes
into the Start stimulus after the response requirement for beginning the
trial has already been met. No significant differences were noted between
groups. (e) Premature responses across both trial types. Premature re-
sponses are responses made into the Go stimulus before the Go stimulus
is presented. A significant main effect of Sex (§p = .028) was noted on
premature responding with males making more premature responses than
females. (f) Mean accuracy responses across all Go trials for the test
session without any significant differences between groups. (g) Mean
reinforcers earned across all Go trials for the test session without any
significant differences between groups
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for POmmision no significant main effect of Sex or Genotype
was noted, nor was there a significant interaction between Sex
and Genotype (Fig. 2b; all p’s > .05). Importantly, there was a
significant interaction of Sex and Genotype on PNo-Go, F (1,
10) = 5.70, p = .038, ω2 = .24 (Fig. 2c), with Tat expression
inducing less inhibitory responses on No-Go trials in females
in contrast to male mice. There was no significant main effect
of Sex or Genotype on PNo-Go (all p’s > .05). When considered
together, this pattern of results indicates that the differences
seen in PInhibition scores are due to a failure of low scorers to
inhibit on No-Go trials and not because of a performance
deficit on Go trials. Thus we can interpret the low scorers as
exhibiting poorer inhibitory control compared to high
scorers.
Additionally, a two-way ANOVA examining differences in
premature responses based on Sex and Genotype revealed a
significant main effect of Sex on premature responses, F (1,
10) = 6.57, p = .028, ω2 = .31 (Fig. 2e). Specifically male mice
(M = 41.57, SEM = 10.58) performed more premature re-
sponses than female mice (M = 10.57, SEM = 2.85). There
was no significant main effect of Genotype nor a significant
interaction between Sex and Genotype of premature re-
sponses (all p’s > .05). Furthermore, on perseverative re-
sponses no significant main effect was noted for Sex or
Genotype, nor a significant Sex by Genotype interaction
(Fig. 2d; all p’s > .05).
Lastly, two variables served as diagnostics to identify if any
subject failed to perform or learn the task, including rein-
forcers earned and accuracy. A two-way ANOVA indicated
that all animals reliably performed the task with no significant
effects found for Sex and/or Genotype on number of rein-
forcers earned (Fig. 2f; all p’s > .05) or accuracy (Fig. 2g; all
p’s > .05). Notably each group earned >40 reinforcers and had
>80% accuracy at test indicating no disruptions in trained
operant behavior during test phase.
Immunohistochemistry
Results from immunohistochemistry staining examining dif-
ferences in CB1R density for the PL and IL regions of the
mPFC are summarized in Fig. 3. A two-way ANOVA on the
PL region revealed no significant main effect of Sex or
Genotype, nor a significant interaction between Sex and
Genotype (Fig. 3d; all p’s > .05). In contrast, a two-way
ANOVA on the IL region revealed a significant main effect
for Sex, F (1, 10) = 8.55, p = .015, ω2 = .21, as well as a sig-
nificant Sex by Genotype interaction, F (1, 10) = 11.36,
p = .007, ω2 = .29. Specifically, female Tat(+) mice (M =
1.97, SEM = .04) showed greater CB1R expression compared
to any other group (Fig. 3e; female Tat(−) mice: M = 1.43,
SEM = .20; p = .023; male Tat(−) mice: M = 1.48, SEM = .11;
p = .026; male Tat(+) mice: M = 1.29, SEM = .01; p = .006).
Relationship between Inhibitory Control and CB1R
Expression
Results of the relationship between PFC-related behavioral
inhibitory control and CB1R expression in the PL and IL re-
gions are summarized in Fig. 4. A Pearson correlation dem-
onstrated no significant correlation between PInhibition and
CB1R expression in the PL region (r = −.371, p = .191; Fig.
4a) but a significant negative correlation for the IL region (r =
−.543, p = .045; Fig. 4b), indicating an association between
inhibitory control deficits and an upregulation of CB1R ex-
pression in the IL of the mPFC. The significant correlation
between inhibitory control and CB1R expression in the IL
region was further assessed by a simple linear regression anal-
ysis using IL CB1R expression as a predictor variable. Results
indicate predictability of PInhibition by CB1R expression in the
IL region accounting for 30% of total variance of inhibitory
control [R2 = .295; F(1, 12) = 5.01, p = .045].
Western Blot Analysis
Results for the female Tat transgenic mice from western blot
analysis for CB1R protein expression are summarized in
Fig. 5. A one-way ANOVA revealed a significant main effect
of Genotype on CB1R protein expression, F (1, 4) = 53.17,
p = .002, ω2 = .90 (Fig. 5b). Specifically, female Tat(+) mice
(M = .80, SEM = .08) demonstrated a significant upregulation
of CB1R protein expression compared the female Tat(−) con-
trol mice (M = .20, SEM = .00).
Electrophysiology
Results from electrophysiology recordings are summarized in
Fig. 6. A two-way ANOVA revealed a significant main effect
of Genotype on sEPSC frequency, F (1, 75) = 7.38, p = .008,
ω2 = .07 (Fig. 6b). Specifically, Tat(+) mice (M = .79,
SEM = .12) showed increased sEPSC frequency compared to
Tat(−) mice (M = .38, SEM = .07). Additionally, a significant
difference was noted between female Tat(−) mice (M = .27,
SEM = .04) and male Tat(+) mice (M = .82, SEM = .13;
p = .026). There was no significant main effect of Sex or Sex
by Genotype interaction on sEPSC frequency (all p’s > .05).
No significant main effects or interaction were noted on
sEPSC amplitude (all p’s > .05; Fig. 6c).
For bath application of PF3845 (1 μM) a one-sample t-test
demonstrated a significant inhibitory effect of PF3845 on per-
cent sEPSC frequency, t(83) = −15.27, p < .001 (Fig. 6e).
Separate one-sample t-tests demonstrated PF3845-induced
percent inhibition for all groups except for male Tat(−) mice
[male Tat(+): t(13) = −14.55, p < .001; female Tat(−): t(27) =
−13.33, p < .001; female Tat(+): t(28) = −10.72, p < .001]. A
two-way ANOVA revealed a significant main effect of
Genotype on percent inhibition of sEPSC frequency by
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PF3845, F (1, 80) = 12.21, p = .001, ω2 = .12. Specifically,
Tat(+) mice (M = −69.24, SEM = 4.54) showed more inhibi-
tion by PF3845 compared to Tat(−) mice (M = −48.18, SEM =
5.91). Additionally, there was a significant interaction be-
tween Sex and Genotype on percent inhibition of sEPSC fre-
quency, F (1, 80) = 4.40, p = .039, ω2 = .04. Specifically male
Tat(−) mice (M = −28.53, SEM = 15.01) demonstrated less in-
hibition by PF3845 compared to male Tat(+) mice (M =
−71.67, SEM = 5.01; p = .006) and compared to female
Tat(+) mice (M = −68.07, SEM = 6.35; p = .003).
For PF3845-induced change on percent sEPSC amplitude,
a one-sample t-tests revealed significant PF3845-induced
Fig. 3 Shows the immunohistochemistry data on CB1R expression. (a)A
representative brain slice (left hemisphere) of a Tat transgenic mouse
stained for Hoechst (blue) with outlining the regions of interest, the PL
and IL in the mPFC. (b)Higher magnification images of the PL region at
20x (b’) and 63x (b”) show staining forMAP2ab (green) and endogenous
CB1R (red), with CB1Rs being specifically localized in the soma of
mPFC neurons. (c) Similarly, higher magnification images of the IL re-
gion at 20x (c’) and 63x (c”) show staining for MAP2ab (green) and
endogenous CB1R (red). (d) CB1R expression is quantified by averaging
the intensity of the CB1R staining per pixel in the PL. No significant
differences were noted between groups. (e) Quantification of CB1R ex-
pression in the IL. There was a significant main effect of Sex (§p = .015)
and a Sex by Genotype interaction for CB1R intensity per pixel
(#p = .007). Specifically, female Tat(+) animals had higher CB1R intensity
compared to any of the other three groups [*p < .05 vs. female Tat(+)].
Scale bars: 20 μm. PL: prelimbic, IL: infralimbic, mPFC: medial prefron-
tal cortex
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inhibition for female Tat(+) mice only, t(28) = −3.11, p = .016
(Fig. 6f). A two-way ANOVA revealed a significant main
effect of Sex, F (1, 80) = 4.45, p = .038, ω2 = .04.
Specifically, female mice (M = −9.43, SEM = 3.41) showed
more inhibition by PF3845 than male mice (M = 2.87, SEM =
5.24). Additionally, there was a significant main effect of
Genotype on percent inhibition of sEPSC amplitude, F (1,
80) = 7.22, p = .009, ω2 = .07. Specifically, Tat(+) mice
(M = −13.31, SEM = 4.25) showed more inhibition by
PF3845 compared to Tat(−) mice (M = 2.73, SEM = 3.58).
There was no significant Sex by Genotype interaction on per-
cent inhibition of sEPSC amplitude (p > .05). Additionally, a
significant difference was noted between male Tat(−) mice
(M = 10.67, SEM = 9.07) and female Tat(+) mice (M =
−17.63, SEM = 5.67; p = .006).
Discussion
The purpose of the current study was to investigate the behav-
ioral profiles of Tat transgenic mice in a PFC-related operant
conditioning task. Specifically in the post-cART era, a sharp
increase has been observed in cortical cognitive deficiencies
(Hardy and Vance 2009; Scott et al. 2011) with HIV-1 patients
displayingmore problems in executive function, memory con-
solidation, and inhibitory control, thus involving the PFC
(Cysique et al. 2004; Garvey et al. 2009; Heaton et al.
2011). Our main objective was to demonstrate that Tat expres-
sion would lead to observable inhibitory control deficits as a
result of prolonged Tat exposure. While it does not appear that
Tat expression alone can account for differences in inhibitory
control, the vulnerability towards prolonged Tat exposure
Fig. 4 Shows the relationship between inhibitory control assessed in the
Go/No-Go task (PInhibition) and CB1R expression assessed by immuno-
histochemistry in the mPFC. (a) A Pearson correlation indicates no sig-
nificant correlation between PInhibition and CB1R expression in the PL
region of the mPFC. (b) For the IL a significant negative correlation
was noted between PInhibition and CB1R expression (*r = −.543,
p = .045), suggesting observed deficits in inhibitory control are associated
with an upregulation in CB1R expression in the IL. A simple linear re-
gressionmodel demonstrates that CB1R expression is able to explain 30%
of the total variance of inhibitory control assessed in the Go/No-Go task
(*R2 = .295, p = .045). PL: prelimbic, IL: infralimbic, mPFC: medial pre-
frontal cortex
Fig. 5 Shows the western blot data on CB1R protein expression in the
mPFC of female Tat transgenic mice. (a) Shows representative
immunoblots for CB1R and β-actin. (b) Quantification of CB1R protein
expression indicated a significant main effect of Genotype (*p = .002)
with female Tat(+) animals demonstrating increased CB1R protein
levels compared to female Tat(−) controls. mPFC: medial prefrontal
cortex
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seems to be sex-dependent. Results from the GNG task dem-
onstrated increased inhibitory control deficits in female Tat(+)
mice on PInhibition compared to their male counterparts. This
holds true despite results on premature responding that did not
mirror the pattern of inhibitory control deficits demonstrated
by PInhibition data, but indicated a sex effect with males
Fig. 6 Details the electrophysiology data on spontaneous excitatory
postsynaptic currents (sEPSCs) assessed in the mPFC in the presence
and absence of PF3845 (1 μM) application. (a) Representative traces
show sEPSCs on PFC brain slices for a control Tat(−) mouse and a
transgenic Tat(+) subject. (b) A significant main effect of Genotype
(¶p = .008) was noted on sEPSC frequency [*p = .026 vs. male Tat(+)].
(c) No significant differences on sEPSC amplitude were noted between
groups. (d)Representative traces show sEPSCs onmPFC brain slices of a
male transgenic Tat(+) subject before and after PF3845 (1 μM) bath
application. (e) A significant effect was noted when applying PF3845
(1 μM) to the bath with PF3845 significantly inhibiting percent sEPSC
frequency for all groups except for male Tat(−) mice [ϕp < .001 vs.
control response (0%) for each of the corresponding groups].
Additionally a significant main effect of Genotype (¶p = .001) was noted
on sEPSC frequency as well as a significant Sex by Genotype interaction
(#p = .039) with male Tat(−) mice showing less inhibition by PF3845
compared to male Tat(+) mice and female Tat(+) subjects [*p < .05 vs.
male Tat(+)]. (f) For the PF3845-induced change on sEPSC amplitude a
significant effect was noted, with PF3845 significantly inhibiting percent
sEPSC amplitude only for female Tat(+) mice [ϕp = .016 vs. control re-
sponse (0%) of female Tat(+) subjects]. Further a significant main effect
of Sex (§p = .038) was noted on PF3845-induced percent inhibition as
well as a significant main effect of Genotype [¶p = .009; *p = .006 vs.
male Tat(−)]. mPFC: medial prefrontal cortex
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emitting more premature responses compared to females. In
past literature, premature responding has been referred to as a
measure of impulsivity, which is best captured through use of
timeouts in the experimental design to implement a negative
consequence to incorrect responses (Bari et al. 2008; Finn
et al. 1999; Robbins 2002). As in the current study the use
of timeouts slowed acquisition of the task to a near standstill,
we removed timeouts for the reported GNG task. Therefore,
premature responses in our study may be better characterized
as an index of hyperactivity rather than impulsivity.
Hyperactivity has been shown to be more prominent in males
in a disease state compared to females (Acharjee et al. 2014;
van den Buuse et al. 2017). Nevertheless, future studies
should attempt to fade in timeouts for various incorrect re-
sponses potentially after the task has been acquired to help
Tat transgenic mice learn the task.
The inhibitory control deficits demonstrated by PInhibition in
our female Tat(+) mice are somewhat surprising as various
past studies have reported higher vulnerability of male trans-
genic Tat(+) mice in different tasks, including rotarod activity
and foregrip strength (Hahn et al. 2015b), and anxiety-like
behaviors (Paris et al. 2014b). The lower vulnerability of fe-
males has suggested to be related to the documented neuro-
protective role of classic steroid hormones estrogen (Hoffman
et al. 2006; Paris et al. 2016; Tang et al. 1996) and its induced
expression of anti-oxidants (Kumar et al. 2011; Rao et al.
2011). Additionally, human literature also supports the notion
of male sex being a risk factor for increasing severity of
HAND symptoms (Joska et al. 2011; Liu et al. 1996).
Nevertheless it should be noted that studies focusing on
HAND in populations exposed to resource-limited environ-
ments reported women to exhibit higher rates and intensity
of symptoms compared to men (Chiesi et al. 1996; Gupta
et al. 2007; Hestad et al. 2012; Wojna et al. 2006). It is sug-
gested that an interaction between environmental stress and
immune function might moderate the relationship between
sex and severity of symptoms. In the current study, food re-
striction of our mice could potentially have served as a source
of stress (Jensen et al. 2013; Yadawa and Chaturvedi 2016).
Future studies may want to look at indicators of stress in the
brain in an attempt to correlate levels of stress with severity of
inhibitory control deficits.
The HIV-1 rodent literature is not devoid of studies that
have shown female rodents to exhibit greater deficits in other
domains of behavior on operant conditioning tasks. Most of
these studies point to sex differences, with females showing a
higher intensity of inflammatory responses in the hippocam-
pus and therefore neuroinflammation serves as a key factor in
accounting for these differences (Devi et al. 2010; Schwarz
and Bilbo 2012; Zhang et al. 2008). There is a need for further
research to investigate sex differences in PFC neuroinflamma-
tion, but available research points to greater expression of
proinflammatory cytokines in female mice following
intermediate ethanol exposure (Pascual et al. 2017). Sex dif-
ferences in neuroinflammation are the likely cause of sex dif-
ferences in signal detection task performance in HIV-1 trans-
genic rats; a recent study demonstrated that female HIV-1
transgenic rats were slower to acquire a signal detection task
and had lower accuracy at test compared to males (McLaurin
et al. 2017). Furthermore, while overall response rates were
much lower for female HIV-1 transgenic rats, female mice
specifically had lower correct rejections, which is akin to the
lower PNo-Go scores characterized in the current study. While
the exact neural mechanisms contributing to differences in
performance on this task require additional exploration, neu-
roinflammation is a mechanism that has been demonstrated to
potentially account for observed behavioral deficits in a num-
ber of disorders including HAND (Appay and Sauce 2008;
Boska et al. 2014; Sas et al. 2007). Furthermore, the contribu-
tion of Tat to neuroinflammation in the CNS to promote neu-
ronal injury and synaptic dysfunction has been reported in
multiple studies in Tat transgenic mouse models (Hahn et al.
2015b; Paris et al. 2015; Paris et al. 2016) and other preclinical
in vivo rodent models, e.g. Tat injections (Marker et al. 2013;
Puccini et al. 2015). Even though an enhanced state of glial
activation and additional evidence of impaired neurogenesis
in the striatum appears to be specifically upregulated in male
Tat(+) mice compared to females (Hahn et al. 2015a; Hahn
et al. 2015b) further studies need to investigate the sex-
dependent effects for neuroinflammation in the PFC.
As the eCB system has attracted interest as a target for
treatment of neurodegenerative disorders, such as
Parkinson’s disease and Alzheimer’s disease (Pertwee 2014;
Scotter et al. 2010), we were interested in investigating the
role of the eCB system, which regulates both immune function
and cognition, as a potential target for treatment of HAND.
When focusing on CB1R expression our immunohistochem-
istry data indicated that female Tat(+) mice who exhibited the
poorest ability of inhibitory control in turn had the greatest
expression of CB1R levels in the IL mPFC. We were able to
confirm this significant upregulation of CB1R expression at
the protein level by western blot analysis with female Tat(+)
mice indicating significant higher CB1R protein expression
levels in the mPFC compared to their control Tat(−) counter-
parts. An upregulation of CB1Rs has been reported in other
experimental disease models, such as Parkinson’s disease
(Brotchie 2003) as well as in brain tissue of HIV-1 infected
patients with encephalitis (Cosenza-Nashat et al. 2011). Our
data showed a correlation between the degree of IL CB1R
upregulation and deficits on the GNG task, specifically on
the ability of our subjects to perform an alternative to the Go
response on No-Go trials, indicating IL machinery was
disrupted in those animals with the highest levels of CB1R
expression. The IL mPFC is important for modifying previ-
ously learned associations allowing the organism to emit al-
ternative behaviors once task parameters become ambiguous
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(Mukherjee and Caroni 2018). In our study, inhibition on No-
Go trials represents an alternative behavior to the Go response
as the same Go stimulus is present on both trial types. In this
way, disrupted functionality of this region accounts for the
decreased probability a subject would emit the alternative re-
sponse on a No-Go trial. Further experiments are needed to
determine if the upregulation of CB1Rs observed in female
Tat(+) mice contributes to the deficits seen in the GNG task
or whether this upregulation is a compensatory response to the
observed Tat-induced inhibitory control deficits in this group.
Upregulation of cannabinoid receptors is seen in a number of
other neurodegenerative disorders, such as Parkinson’s dis-
ease and Alzheimer’s disease, however their role is disease
progression is still unclear (Benito et al. 2003; Farkas et al.
2012; Lastres-Becker et al. 2001; Lee et al. 2010; Ramirez
et al. 2005; Van Laere et al. 2009; Westlake et al. 1994).
Nevertheless, even though our data support the notion of an
upregulation in CB1R expression, decreased or no change in
CB1R expression has also been reported in a disease state
depending on the brain region involved (Bedse et al. 2014;
Benito et al. 2005; Silverdale et al. 2001). Further, as brain
inflammation is a common feature in HIV-1 infection, an up-
regulation of CB2R appears to play an important role in HIV-1
encephalitis and simian immunodeficiency virus (SIV)
(Benito et al. 2005; Cosenza-Nashat et al. 2011). While
CB1R is abundantly expressed in the cortex specifically on
pyramidal neurons, CB2R is expressed sparingly throughout
the cortex but the greatest population exists on glial cells
(Benito et al. 2008; Marsicano and Lutz 1999; Tsou et al.
1998). Quantitative image analysis of brains from HIV-1 in-
fected patients with encephalitis indicated significant in-
creases in CB2R expression in microglia, astrocytes and
perivascular macrophages (Cosenza-Nashat et al. 2011).
Despite the conflicting literature on changes in CB1R and
CB2R expression levels in disease, it is agreed that the eCB
system is a key modulator of synaptic function and is impli-
cated in the progression of neurodegenerative disorders.
For synaptic function, the current study was able to dem-
onstrate a significant disruption of synaptic function in the
mPFC as indicated by the increased sEPSC frequency in
Tat(+) mice compared to their Tat(−) counterparts (males
and females). Enhanced glutamatergic neurotransmission by
Tat has been demonstrated in previous in vitro studies
(Brailoiu et al. 2008; Green and Thayer 2016; Musante et al.
2010; Xu et al. 2017) and is suggested to be mediated via Tat’s
actions on NMDARs (Eugenin et al. 2007; Green and Thayer
2016; Raybuck et al. 2017) as well as non-NMDARs (Nath
et al. 1996), leading to calcium influx, oxidative stress, and
neuronal injury (Kaul et al. 2001). The Tat-induced increases
in excitability, with the enhancement of the sEPSCs frequency
but not affecting their amplitude has been reported recently
in vitro (Xu et al. 2017) and suggests a presynaptic stimulatory
effect on glutamate release (Brailoiu et al. 2008). Interestingly,
CB1R stimulation has been demonstrated to limit glutamate-
mediated synaptic excitation (Rossi et al. 2011). The involve-
ment of the CB1Rs located on glutamatergic terminals is crit-
ical for the neuroprotective effects of eCBs in counteracting
excitotoxicity (Chiarlone et al. 2014). It is known that upon
excessive glutamate release, eCBs are produced
perisynaptically to engage with presynaptic CB1Rs to inhibit
excitatory transmission thus buffering against the excitotoxic
effects of NMDAR activity in the postsynaptic neuron
(Chiarlone et al. 2014; Huang et al. 2001). Various studies
have shown that CB1Rs mediate the neuroprotective effects
that eCBs exhibit against excitotoxic damage and inflamma-
tion (Shen and Thayer 1998; Xu et al. 2017). However, even
though the activation of CB1Rs is known to be neuroprotec-
tive, therapeutic use of direct CB1R agonist is limited due to
the pervasive psychoactive side effects associated with CB1R
agonists that include sensorimotor, affective and cognitive
disturbances (Di Marzo 2008). Additionally, given the speed
at which eCBs are broken down, administration of eCB li-
gands is sure to have only a transient impact as they are im-
mediately degraded by their corresponding eCB-metabolizing
enzymes (Blankman and Cravatt 2013). Thus, neuroprotec-
tive effects can be achieved using eCB enzyme inhibitors,
such as inhibiting the main AEA-metabolizing enzyme fatty
acid amide hydrolase (FAAH), as demonstrated in a recent
in vitro primary PFC neuron culture study in the context of
Tat-toxicity (Hermes et al. 2018). Indeed, in the present study
by using the FAAH enzyme inhibitor PF3845, which acts on
CB1R-related mechanisms, Tat-induced increase on sEPSCs
frequency was attenuatedwhen bath applied, with Tat(+) brain
slices being affected significantly more compared to Tat(−)
brain slices (male and females). These results point towards
neuroprotective effects by modulating eCB enzyme activity,
potentially due to upregulation of AEA levels by PF3845.
Noteworthy, in the context of Tat toxicity the upregulation
of eCB signaling by PF3845 has been shown to not only
dependent on CB1R-dependent mechanisms but also CB2R
involvement (Hermes et al. 2018). Additionally, FAAH en-
zyme inhibition can also elevate non-cannabinoid lipid medi-
a t o r s ( e .g . , pa lm i toy l e t hano l am ide (PEA) and
oleoylethanolamide (OEA)), which produce anti-
inflammatory effects through a non-CR-mediated mechanism
of action (i.e., peroxisome proliferator-activated receptor al-
pha). Despite the finding that PF3845 involves more than just
CB1R-related mechanisms, our current study indicates the
possibility for future studies to modulate the eCB system
in vivo and examine the influence on Tat-induced behavioral
deficits.
Conclusion
In conclusion, the results of the present study indicate that the
GNG task is a viablemethod to assess inhibitory control deficits
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associated with HAND in the Tat transgenic mouse model.
Female Tat(+) animals showed greater inhibitory control defi-
cits which is most likely due to sex differences in inflammatory
responses to excitotoxic injury. These deficits are associated
with an upregulation of CB1R. Further experiments are required
to determine whether the observed CB1R upregulation is a
compensatory response to Tat induced excitotoxicity or is con-
tributing to the deficit as a part of disease pathogenesis. Tat also
leads to an increase in sEPSCs, which may indicate a mecha-
nism for how Tat eventually results in excitotoxic injury. These
increases in sEPSC are attenuated by an eCB enzyme inhibitor,
PF3845. Taken together, these results indicate a viable strategy
to address damage precipitated by Tat may come in the form of
therapies that modulate activity of the eCB system through use
of enzyme inhibitors.
Acknowledgments The authors of this manuscript would like to thank
Alanna B. Fergusson, Alexis Antonucci, Camila Manjarres, Alexandra
M. Proca, Camille B. Russel, Natalie R. Miseo, Amanda M. Dalmau, and
Kaylynn L. Leggette for their work on the operant conditioning experi-
ments. The authors would also like to acknowledge the work of animal
care technicianDeVeda Eubanks for her role inmaintaining the welfare of
our animals through the studies. We gratefully acknowledge the support
from the National Institute on Drug Abuse (NIDA R01 DA045596, R21
DA041903, R21 DA045597, T32 DA007244, R01 DA039942, and R01
DA033760) and from the National Institute of Allergy and Infectious
Diseases (NIAID R01 AI128864, and R01 AI091526). Bogna M.
Ignatowska-Jankowska was supported by the fellowship from the Japan
Society for Promotion of Science (JSPS) and Grant-in-Aid for JSPS fel-
lows 17F17388.
Compliance with Ethical Standards
Ethical Approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All
procedures performed in studies involving animals were in accordance
with the ethical standards of the institution or practice at which the studies
were conducted.
Conflict of Interest The authors declare that they have no conflicts of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Acharjee S, Branton WG, Vivithanaporn P, Maingat F, Paul AM, Dickie
P, Baker GB, Power C (2014) HIV-1 Nef expression in microglia
disrupts dopaminergic and immune functions with associated
mania-like behaviors. Brain Behav Immun 40:74–84. https://doi.
org/10.1016/j.bbi.2014.02.016
Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that
regulate endocannabinoid signaling in the nervous system. Chem
Rev 108:1687–1707. https://doi.org/10.1021/cr0782067
Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK,
Weerapana E, Sadagopan N, Liimatta M, Smith SE, Lazerwith S,
Stiff C, Kamtekar S, Bhattacharya K, Zhang Y, Swaney S, Van
Becelaere K, Stevens RC, Cravatt BF (2009) Discovery and char-
acterization of a highly selective FAAH inhibitor that reduces in-
flammatory pain. Chem Biol 16:411–420. https://doi.org/10.1016/j.
chembiol.2009.02.013
Andre VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William
Yang X, Levine MS (2010) Dopamine modulation of excitatory
currents in the striatum is dictated by the expression of D1 or D2
receptors andmodified by endocannabinoids. Eur J Neurosci 31:14–
28. https://doi.org/10.1111/j.1460-9568.2009.07047.x
Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1
infection: causes and consequences. J Pathol 214:231–241. https://
doi.org/10.1002/path.2276
Bari A, Dalley JW, Robbins TW (2008) The application of the 5-choice
serial reaction time task for the assessment of visual attentional
processes and impulse control in rats. Nat Protoc 3:759–767.
https://doi.org/10.1038/nprot.2008.41
Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR,
Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano T, Gaetani S
(2014) Altered expression of the CB1 cannabinoid receptor in the
triple transgenic mouse model of Alzheimer's disease. J Alzheimers
Dis 40:701–712. https://doi.org/10.3233/JAD-131910
Benito C, Nunez E, Tolon RM, Carrier EJ, RabanoA,Hillard CJ, Romero
J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase
are selectively overexpressed in neuritic plaque-associated glia in
Alzheimer's disease brains. J Neurosci 23:11136–11141
Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM,
Williams K, Romero J (2005) A glial endogenous cannabinoid sys-
tem is upregulated in the brains of macaques with simian immuno-
deficiency virus-induced encephalitis. J Neurosci 25:2530–2536.
https://doi.org/10.1523/JNEUROSCI.3923-04.2005
Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J (2008)
Cannabinoid CB2 receptors in human brain inflammation. Br J
Pharmacol 153:277–285. https://doi.org/10.1038/sj.bjp.0707505
Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid
metabolism. Pharmacol Rev 65:849–871. https://doi.org/10.1124/
pr.112.006387
Booker L, Kinsey, SG, Abdullah, RA, Blankman, JL, Long, JZ, Ezzili, C,
Boger, DL, Cravatt, , BF, Lichtman, AH (2012) The fatty acid amide
hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to
reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 165:
2485–2496 doi:https://doi.org/10.1111/j.1476-5381.2011.01445.x
Boska MD, Dash PK, Knibbe J, Epstein AA, Akhter SP, Fields N, High
R, Makarov E, Bonasera S, Gelbard HA, Poluektova LY,
Gendelman HE, Gorantla S (2014) Associations between brain mi-
crostructures, metabolites, and cognitive deficits during chronic
HIV-1 infection of humanized mice. Molecular Neurodegeneration
9:58. https://doi.org/10.1186/1750-1326-9-58
Brailoiu GC, Brailoiu E, Chang JK, Dun NJ (2008) Excitatory effects of
human immunodeficiency virus 1 tat on cultured rat cerebral cortical
neurons. Neuroscience 151:701–710. https://doi.org/10.1016/j.
neuroscience.2007.11.031
Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson's
disease. Curr Opin Pharmacol 3:54–61. https://doi.org/10.1016/
s1471-4892(02)00011-5
Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A,
Reid R, Xu R, Nath A, Knapp PE, Hauser KF (2008) Morphine
causes rapid increases in glial activation and neuronal injury in the
striatum of inducible HIV-1 Tat transgenic mice. Glia 56:1414–
1427. https://doi.org/10.1002/glia.20708
Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012)
Expression of HIV-Tat protein is associated with learning and mem-
ory deficits in the mouse. Behav Brain Res 229:48–56. https://doi.
org/10.1016/j.bbr.2011.12.019
J Neuroimmune Pharmacol (2019) 14:661–678674
Chen P, Mayne M, Power C, Nath A (1997) The tat protein of HIV-1
induces tumor necrosis factor-alpha production. Implications for
HIV-1-associated neurological diseases. J Biol Chem 272:22385–
22388
Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, MaM, Magnuson
DS (1998) Neuronal excitatory properties of human immunodefi-
ciency virus type 1 tat protein. Neuroscience 82:97–106
Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-
mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:
37–76. https://doi.org/10.1146/annurev.neuro.29.051605.112834
Chiarlone A, Bellocchio L, Blazquez C, Resel E, Soria-Gomez E,
Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sanchez-
Prieto J, Lutz B, Fernandez-Ruiz J, Galve-Roperh I, Guzman M
(2014) A restricted population of CB1 cannabinoid receptors with
neuroprotective activity. Proc Natl Acad Sci U S A 111:8257–8262.
https://doi.org/10.1073/pnas.1400988111
Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM,
Schwander S, Goebel FD, Glauser M, Antunes F, Lundgren JD
(1996) Epidemiology of AIDS dementia complex in Europe AIDS
in Europe Study Group. J Acquir Immune Defic Syndr Hum
Retrovirol 11:39–44
Connolly CG, Bischoff-Grethe A, Jordan SJ, Woods SP, Ellis RJ, Paulus
MP, Grant I (2014) Altered functional response to risky choice in
HIV infection. PLoS One 9:e111583. https://doi.org/10.1371/
journal.pone.0111583
Cosenza-NashatMA, BaumanA, ZhaoML,Morgello S, SuhHS, Lee SC
(2011) Cannabinoid receptor expression in HIV encephalitis and
HIV-associated neuropathologic comorbidities. Neuropathol Appl
Neurobiol 37:464–483. https://doi.org/10.1111/j.1365-2990.2011.
01177.x
Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuro-
psychological impairment in human immunodeficiency virus-infect-
ed/acquired immunodeficiency syndrome (HIV/AIDS) patients
across pre- and post-highly active antiretroviral therapy eras: a com-
bined study of two cohorts. J Neurovirol 10:350–357. https://doi.
org/10.1080/13550280490521078
Devi L, AlldredMJ, Ginsberg SD, OhnoM (2010) Sex- and brain region-
specific acceleration of beta-amyloidogenesis following behavioral
stress in a mouse model of Alzheimer's disease. Mol Brain 3:34.
https://doi.org/10.1186/1756-6606-3-34
Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or
reduce? Nat Rev Drug Discov 7:438–455. https://doi.org/10.1038/
nrd2553
El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF (2005)
Synergistic increases in intracellular Ca2+, and the release of MCP-
1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1
tat. Glia 50:91–106. https://doi.org/10.1002/glia.20148
El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp
PE, Hauser KF (2008) Morphine exacerbates HIV-1 tat-induced
cytokine production in astrocytes through convergent effects on
[Ca2+]i, NF-κB trafficking and transcription. PLoS One 3:e4093.
https://doi.org/10.1371/journal.pone.0004093
Ellis R, Langford D, Masliah E (2007) HIVand antiretroviral therapy in
the brain: neuronal injury and repair. Nat Rev Neurosci 8:33–44.
https://doi.org/10.1038/nrn2040
Ernst T, Chang L, Arnold S (2003) Increased glial metabolites predict
increased working memory network activation in HIV brain injury.
Neuroimage 19:1686–1693
Eugenin EA, King JE, Nath A, Calderon TM, Zukin RS, Bennett MV,
Berman JW (2007) HIV-tat induces formation of an LRP-PSD-95-
NMDAR-nNOS complex that promotes apoptosis in neurons and
astrocytes proc. Natl Acad Sci U S a 104:3438–3443. https://doi.org/
10.1073/pnas.0611699104
Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson
JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density
is reduced in mild to moderate human immunodeficiency virus
neurocognitive disorder. HIV Neurobehavioral Research Center
Brain Pathol 9:209–217
Farkas S, Nagy K, Palkovits M, Kovacs GG, Jia Z, Donohue S, Pike V,
Halldin C, Mathe D, Harkany T, Gulyas B, Csiba L (2012)
[(1)(2)(5)I]SD-7015 reveals fine modalities of CB(1) cannabinoid
receptor density in the prefrontal cortex during progression of
Alzheimer's disease. Neurochem Int 60:286–291. https://doi.org/
10.1016/j.neuint.2011.11.004
Finn PR, Justus A, Mazas C, Steinmetz JE (1999) Working memory,
executive processes and the effects of alcohol on go/no-go learning:
testing a model of behavioral regulation and impulsivity.
Psychopharmacology 146:465–472
Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser
KF (2010) Interactive comorbidity between opioid drug abuse and
HIV-1 Tat: chronic exposure augments spine loss and sublethal den-
dritic pathology in striatal neurons. Am J Pathol 177:1397–1410.
https://doi.org/10.2353/ajpath.2010.090945
Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI,
Hauser KF (2014) Interactive HIV-1 tat and morphine-induced
synaptodendritic injury is triggered through focal disruptions in
Na+ influx, mitochondrial instability, and Ca2+ overload. J
Neurosci 34:12850–12864. https://doi.org/10.1523/JNEUROSCI.
5351-13.2014
Garvey LJ, Yerrakalva D, Winston A (2009) Correlations between com-
puterized battery testing and a memory questionnaire for identifica-
tion of neurocognitive impairment in HIV type 1-infected subjects
on stable antiretroviral therapy AIDS. Res Hum Retroviruses 25:
765–769. https://doi.org/10.1089/aid.2008.0292
GreenMV, Thayer SA (2016) NMDARs adapt to neurotoxic HIV protein
tat downstream of a GluN2A-ubiquitin ligase signaling pathway. J
Neurosci 36(50):12640–12649. https://doi.org/10.1523/
JNEUROSCI.2980-16.2016
Green MV, Raybuck JD, Zhang X, Wu MM, Thayer SA (2018) Scaling
synapses in the presence of HIV. Neurochem Res. https://doi.org/10.
1007/s11064-018-2502-2
Gubner NR, Wilhelm CJ, Phillips TJ, Mitchell SH (2010) Strain differ-
ences in behavioral inhibition in a go/no-go task demonstrated using
15 inbredmouse strains alcohol. Clin Exp res 34:1353–1362. https://
doi.org/10.1111/j.1530-0277.2010.01219.x
Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde
D, Ellis R, Ownby R, Subbakrishna DK, Desai A, Kamat A, Ravi V,
Rao BS, Satish KS, KumarM (2007) Neuropsychological deficits in
human immunodeficiency virus type 1 clade C-seropositive adults
from South India. J Neurovirol 13:195–202. https://doi.org/10.1080/
13550280701258407
Hahn YK, Masvekar RR, Xu R, Hauser KF, Knapp PE (2015a) Chronic
HIV-1 tat and HIV reduce Rbfox3/NeuN: evidence for sex-related
effects. Curr HIV res 13:10–20
Hahn YK, Podhaizer EM, Farris SP, Miles MF, Hauser KF, Knapp PE
(2015b) Effects of chronic HIV-1 tat exposure in the CNS: height-
ened vulnerability of males versus females to changes in cell num-
bers, synaptic integrity, and behavior brain. Struct Funct 220:605–
623. https://doi.org/10.1007/s00429-013-0676-6
Hardy DJ, Vance DE (2009) The neuropsychology of HIV/AIDS in older
adults. Neuropsychol Rev 19:263–272. https://doi.org/10.1007/
s11065-009-9087-0
Harkany T, Mackie K, Doherty P (2008) Wiring and firing neuronal
networks: endocannabinoids take center stage. Curr Opin
Neurobiol 18:338–345. https://doi.org/10.1016/j.conb.2008.08.007
Harrison KM, Song R, Zhang X (2010) Life expectancy after HIV diag-
nosis based on national HIV surveillance data from 25 states, United
States. J Acquir Immune Defic Syndr 53:124–130. https://doi.org/
10.1097/QAI.0b013e3181b563e7
Haughey NJ, Holden CP, Nath A, Geiger JD (1999) Involvement of
inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium
J Neuroimmune Pharmacol (2019) 14:661–678 675
in calcium dysregulation and neuron cell death caused by HIV-1
protein tat. J Neurochem 73:1363–1374
Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, Bruce-Keller
AJ, Knapp PE (2009) HIV-1 Tat and Morphine Have Interactive
Effects on Oligodendrocyte Survival and Morphology. Glia 57:
194–206. https://doi.org/10.1002/glia.20746
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc
S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC,
Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD,
Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson
DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL,
Wong J, Grant I, Group C, Group H (2011) HIV-associated
neurocognitive disorders before and during the era of combination
antiretroviral therapy: differences in rates, nature, and predictors. J
Neurovirol 17:3–16. https://doi.org/10.1007/s13365-010-0006-1
Hermes DJ, Xu C, Poklis JL, Niphakis MJ, Cravatt BF, Mackie K,
Lichtman AH, Ignatowska-Jankowska BM, Fitting S (2018)
Neuroprotective effects of fatty acid amide hydrolase catabolic en-
zyme inhibition in a HIV-1 Tat model of neuroAIDS.
Neuropharmacology 141:55–65. https://doi.org/10.1016/j.
neuropharm.2018.08.013
Hestad KA, Menon JA, Silalukey-Ngoma M, Franklin DR Jr, Imasiku
ML, Kalima K, Heaton RK (2012) Sex differences in neuropsycho-
logical performance as an effect of human immunodeficiency virus
infection: a pilot study in Zambia, Africa. J NervMent Dis 200:336–
342. https://doi.org/10.1097/NMD.0b013e31824cc225
Hoffman GE, Merchenthaler I, Zup SL (2006) Neuroprotection by ovar-
ian hormones in animal models of neurological disease. Endocrine
29:217–231. https://doi.org/10.1385/ENDO:29:2:217
Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying
cannabinoid inhibition of excitatory synaptic transmission in rat
striatal neurons. J Physiol 532:731–748
Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis
MJ, Abdullah RA, Tao Q, O’ Neal ST, Walentiny DM, Wiley JL,
AH CBFL (2014) In vivo characterization of the highly selective
monoacylglycerol lipase inhibitor KML29: antinociceptive activity
without cannabimimetic side effects. Br J Pharmacol 171:1392–
1407. https://doi.org/10.1111/bph.12298
Ignatowska-Jankowska B, Wilkerson, JL, Mustafa, M, Abdullah, R,
Niphakis, M, Wiley, JL, Cravatt, BF, Lichtman, A. H. (2015)
Selective monoacylglycerol lipase inhibitors: antinociceptive versus
cannabimimetic effects inmice. J Pharmacol Exp Ther 353:424–432
doi:https://doi.org/10.1124/jpet.114.222315
Jensen TL, Kiersgaard MK, Sorensen DB, Mikkelsen LF (2013) Fasting
of mice: a review. Lab Anim 47(4):225–240. https://doi.org/10.
1177/0023677213501659
Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R,
Nath A (2013) Induction of IL-17 and nonclassical T-cell activation
by HIV-tat protein proc. Natl Acad Sci U S a 110:13588–13593.
https://doi.org/10.1073/pnas.1308673110
Joska JA, Westgarth-Taylor J, Myer L, Hoare J, Thomas KG, Combrinck
M, Paul RH, Stein DJ, Flisher AJ (2011) Characterization of HIV-
Associated Neurocognitive Disorders among individuals starting
antiretroviral therapy in South Africa AIDS. Behav 15:1197–1203.
https://doi.org/10.1007/s10461-010-9744-6
Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and
apoptosis in HIV-associated dementia. Nature 410:988–994. https://
doi.org/10.1038/35073667
Kesby JP, Hubbard DT, Markou A, Semenova S (2014) Expression of
HIV gp120 protein increases sensitivity to the rewarding properties
of methamphetamine in mice addiction. Biology 19:593–605.
https://doi.org/10.1111/adb.12023
Kesby JP, Markou A, Semenova S, Translational Methamphetamine
ARCG (2015) Cognitive deficits associated with combined HIV
gp120 expression and chronic methamphetamine exposure in mice.
Eur Neuropsychopharmacol 25:141–150. https://doi.org/10.1016/j.
euroneuro.2014.07.014
Kumar P, Kale RK, McLean P, Baquer NZ (2011) Protective effects of
17beta estradiol on altered age related neuronal parameters in female
rat brain. Neurosci Lett 502:56–60. https://doi.org/10.1016/j.neulet.
2011.07.024
Kutsch O, Oh J, Nath A, Benveniste EN (2000) Induction of the
chemokines interleukin-8 and IP-10 by human immunodeficiency
virus type 1 tat in astrocytes. J Virol 74:9214–9221
Lastres-Becker I, CebeiraM, de CeballosML, Zeng BY, Jenner P, Ramos
JA, Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor
binding and activation of GTP-binding proteins in the basal ganglia
of patients with Parkinson's syndrome and ofMPTP-treated marmo-
sets Eur J Neurosci 14:1827-1832
Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT,
Wong PT, Chen CP, Lai MK (2010) Intact cannabinoid CB1 recep-
tors in the Alzheimer's disease cortex Neurochem Int 57:985-989.
https://doi.org/10.1016/j.neuint.2010.10.010
Lichtman AH, Blankman JL, Cravatt BF (2010) Endocannabinoid over-
load. Mol Pharmacol 78:993–995. https://doi.org/10.1124/mol.110.
069427
Lipton SA (1993) Human immunodeficiency virus-infected macro-
phages, gp120, and N-methyl-D-aspartate receptor-mediated neuro-
toxicity. Ann Neurol 33:227–228. https://doi.org/10.1002/ana.
410330218
Liu X, Marder K, Stern Y, Dooneief G, Bell K, Todak G, Joseph M,
Elsadr W, Williams JB, Ehrhardt A, Stein Z, Mayeux R (1996)
Gender differences in HIV-related neurological progression in a co-
hort of injecting drug users followed for 3.5 years. J NeuroAIDS 1:
17–30
Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, Moir RD,
Nath A, He JJ (2000) Uptake of HIV-1 tat protein mediated by low-
density lipoprotein receptor-related protein disrupts the neuronal
metabolic balance of the receptor ligands. Nat med 6:1380–1387.
https://doi.org/10.1038/82199
Liu Q, Bhat M, Bowen WD, Cheng J (2009) Signaling pathways from
cannabinoid receptor-1 activation to inhibition of N-methyl-D-
aspartic acid mediated calcium influx and neurotoxicity in dorsal
root ganglion neurons. J Pharmacol Exp Ther 331:1062–1070.
https://doi.org/10.1124/jpet.109.156216
Longordo F, Feligioni M, Chiaramonte G, Sbaffi PF, Raiteri M, Pittaluga
A (2006) The human immunodeficiency virus-1 protein
transactivator of transcription up-regulates N-methyl-D-aspartate re-
ceptor function by acting at metabotropic glutamate receptor 1 re-
ceptors coexisting on human and rat brain noradrenergic neurones. J
Pharmacol Exp Ther 317:1097–1105. https://doi.org/10.1124/jpet.
105.099630
Loos M, Staal J, Schoffelmeer ANM, Smit AB, Spijker S, Pattij T (2010)
Inhibitory control and response latency differences between C57BL/
6J and DBA/2J mice in a go/no-go and 5-choice serial reaction time
task and strain-specific responsivity to amphetamine. Behavioural
brain research 214:216–224. https://doi.org/10.1016/j.bbr.2010.05.
027
MagnusonDS, Knudsen BE, Geiger JD, Brownstone RM, Nath A (1995)
Human immunodeficiency virus type 1 tat activates non-N-methyl-
D-aspartate excitatory amino acid receptors and causes neurotoxic-
ity. Ann Neurol 37:373–380. https://doi.org/10.1002/ana.
410370314
Marker DF, Tremblay ME, Puccini JM, Barbieri J, Gantz Marker MA,
Loweth CJ, Muly EC, Lu SM, Goodfellow VS, Dewhurst S,
Gelbard HA (2013) The new small-molecule mixed-lineage kinase
3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in
models of human immunodeficiency virus-associated
neurocognitive disorders. J Neurosci 33:9998–10010. https://doi.
org/10.1523/JNEUROSCI.0598-13.2013
J Neuroimmune Pharmacol (2019) 14:661–678676
Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR,
Knapp PE, Hauser KF (2016) HIV-1 tat causes cognitive deficits
and selective loss of parvalbumin, somatostatin, and neuronal nitric
oxide synthase expressing hippocampal CA1 interneuron subpopu-
lations. J Neurovirol 22:747–762. https://doi.org/10.1007/s13365-
016-0447-2
Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1
in distinct neuronal subpopulations in the adult mouse forebrain. Eur
J Neurosci 11:4213–4225
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich
A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-
Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di
Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and
on-demand defense against excitotoxicity. Science 302:84–88.
https://doi.org/10.1126/science.1088208
Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M,
Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997)
Dendritic injury is a pathological substrate for human immunodefi-
ciency virus-related cognitive disorders. The HIV Neurobehavioral
Research Center Ann Neurol 42:963–972. https://doi.org/10.1002/
ana.410420618
MattsonMP, Haughey NJ, Nath A (2005) Cell death in HIV dementia cell
death differ. 12 Suppl 1:893-904. https://doi.org/10.1038/sj.cdd.
4401577
Maung R, Hoefer MM, Sanchez AB, Sejbuk NE, Medders KE, Desai
MK, Catalan IC, Dowling CC, de Rozieres CM, Garden GA, Russo
R, Roberts AJ, Williams R, Kaul M (2014) CCR5 knockout pre-
vents neuronal injury and behavioral impairment induced in a trans-
genic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J
Immunol 193:1895–1910. https://doi.org/10.4049/jimmunol.
1302915
McLaurin KA, Booze RM, Mactutus CF, Fairchild AJ (2017) Sex mat-
ters: robust sex differences in signal detection in the HIV-1 trans-
genic rat front. Behav Neurosci 11:212. https://doi.org/10.3389/
fnbeh.2017.00212
Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H,
Mokhtari M, Moreau H, Tamalet C, Brunet C, Paul P, Dignat-
George F, Stein A, Brouqui P, Spector SA, Campbell GR, Loret
EP (2012) Antiretroviral therapy does not block the secretion of
the human immunodeficiency virus tat protein. Infect Disord Drug
Targets 12:81–86
Mediouni S, Jablonski J, Paris JJ, Clementz MA, Thenin-Houssier S,
McLaughlin JP, Valente ST (2015) Didehydro-cortistatin a inhibits
HIV-1 tat mediated neuroinflammation and prevents potentiation of
cocaine reward in tat transgenic mice. Curr HIV res 13:64–79
Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R,
Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL,
Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt
HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR,
Marsicano G, Lutz B (2006) The endocannabinoid system controls
key epileptogenic circuits in the hippocampus. Neuron 51:455–466.
https://doi.org/10.1016/j.neuron.2006.07.006
Mukherjee A, Caroni P (2018) Infralimbic cortex is required for learning
alternatives to prelimbic promoted associations through reciprocal
connectivity. Nature Communications 9 doi:https://doi.org/10.1038/
s41467-018-05318-x
Musante V, Summa M, Neri E, Puliti A, Godowicz TT, Severi P,
Battalglia G, Raiteri M, Pittaluga A (2010) The HIV-1 viral protein
tat increases glutamate and decreases GABA exocytosis from hu-
man and mouse neocortical nerve endings. Cereb Cortex 20(8):
1974–1984. https://doi.org/10.1093/cercor/bhp274
Naidoo V, Nikas SP, Karanian DA, Hwang J, Zhao J,Wood JT, Alapafuja
SO, Vadivel SK, Butler D, Makriyannis A, Bahr BA (2011) A new
generation fatty acid amide hydrolase inhibitor protects against
kainate-induced excitotoxicity. J Mol Neurosci 43:493–502.
https://doi.org/10.1007/s12031-010-9472-4
Nath A (2002) Human immunodeficiency virus (HIV) proteins in
neuropathogenesis of HIV dementia. J infect dis 186(Suppl 2):
S193–S198. https://doi.org/10.1086/344528
Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N,
Geiger JD (1996) Identification of a human immunodeficiency virus
type 1 tat epitope that is neuroexcitatory and neurotoxic. J Virol 70:
1475–1480
Niphakis MJ, Cognetta AB 3rd, Chang JW, Buczynski MW, Parsons LH,
Byrne F, Burston JJ, Chapman V, Cravatt BF (2013) Evaluation of
NHS carbamates as a potent and selective class of endocannabinoid
hydrolase inhibitors ACS. ChemNeurosci 4:1322–1332. https://doi.
org/10.1021/cn400116z
Paris JJ, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP (2014a)
Effects of conditional central expression of HIV-1 tat protein to
potentiate cocaine-mediated psychostimulation and reward among
male mice. Neuropsychopharmacology 39:380–388. https://doi.org/
10.1038/npp.2013.201
Paris JJ, Fenwick J, McLaughlin JP (2014b) Progesterone protects nor-
mative anxiety-like responding among ovariectomized female mice
that conditionally express the HIV-1 regulatory protein, Tat, in the
CNS. Hormones and behavior 65:445–453. https://doi.org/10.1016/
j.yhbeh.2014.04.001
Paris JJ, Singh HD, Ganno ML, Jackson P, McLaughlin JP (2014c)
Anxiety-like behavior of mice produced by conditional central ex-
pression of the HIV-1 regulatory protein, Tat. Psychopharmacology
(Berl) 231:2349–2360. https://doi.org/10.1007/s00213-013-3385-1
Paris JJ, SinghHD, Carey AN,McLaughlin JP (2015) Exposure to HIV-1
tat in brain impairs sensorimotor gating and activates microglia in
limbic and extralimbic brain regions of male mice. Behav brain res
291:209–218. https://doi.org/10.1016/j.bbr.2015.05.021
Paris JJ, Zou S, Hahn YK, Knapp PE, Hauser KF (2016) 5alpha-reduced
progestogens ameliorate mood-related behavioral pathology, neuro-
toxicity, and microgliosis associated with exposure to HIV-1 tat
brain, behavior, and immunity. https://doi.org/10.1016/j.bbi.2016.
01.007
Parker LA, Niphakis MJ, Downey R, Limebeer CL, Rock EM, Sticht
MA, Morris H, Abdullah RA, Lichtman AH, Cravatt BF (2015)
Effect of selective inhibition of monoacylglycerol lipase (MAGL)
on acute nausea, anticipatory nausea, and vomiting in rats and
Suncus murinus. Psychopharmacology (Berl) 232:583–593.
https://doi.org/10.1007/s00213-014-3696-x
Pascual M, Montesinos J, Marcos M, Torres JL, Costa-Alba P, Garcia-
Garcia F, Laso FJ, Guerri C (2017) Gender differences in the inflam-
matory cytokine and chemokine profiles induced by binge ethanol
drinking in adolescence. Addict Biol 22:1829–1841. https://doi.org/
10.1111/adb.12461
Pertwee RG (2014) Elevating endocannabinoid levels: pharmacological
strategies and potential therapeutic applications proc. Nutr Soc 73:
96–105. https://doi.org/10.1017/S0029665113003649
Petrosino S, Di Marzo V (2010) FAAH and MAGL inhibitors: therapeu-
tic opportunities from regulating endocannabinoid levels. Curr Opin
Investig Drugs 11:51–62
Puccini JM, Marker DF, Fitzgerald T, Barbieri J, Kim CS, Miller-Rhodes
P, Lu SM, Dewhurst S, Gelbard HA (2015) Leucine-rich repeat
kinase 2 modulates neuroinflammation and neurotoxicity in models
of human immunodeficiency virus 1-associated neurocognitive dis-
orders. J Neurosci 35:5271–5283. https://doi.org/10.1523/
JNEUROSCI.0650-14.2015
Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos
ML (2005) Prevention of Alzheimer's disease pathology by canna-
binoids: neuroprotection mediated by blockade of microglial activa-
tion. J Neurosci 25:1904–1913. https://doi.org/10.1523/
JNEUROSCI.4540-04.2005
Rao AK, Dietrich AK, Ziegler YS, Nardulli AM (2011) 17beta-estradiol-
mediated increase in cu/Zn superoxide dismutase expression in the
brain: a mechanism to protect neurons from ischemia the journal of
J Neuroimmune Pharmacol (2019) 14:661–678 677
steroid biochemistry and molecular. Biology 127:382–389. https://
doi.org/10.1016/j.jsbmb.2011.06.008
Raybuck JD, Hargus NJ, Thayer SA (2017) A GluN2B-selective
NMDAR antagonist reverses synapse loss and cognitive impairment
produced by the HIV-1 protein tat. J Neurosci 37:7837–7847.
https://doi.org/10.1523/JNEUROSCI.0226-17.2017
Robbins TW (2002) The 5-choice serial reaction time task: behavioural
pharmacology and functional neurochemistry. Psychopharmacology
(Berl) 163:362–380. https://doi.org/10.1007/s00213-002-1154-7
Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V,
Cavasinni F, Bernardi G, Martino G, Cravatt BF, Lutz B,
MaccarroneM, Centonze D (2011) Cannabinoid CB1 receptors reg-
ulate neuronal TNF-alpha effects in experimental autoimmune en-
cephalomyelitis brain. Behav Immun 25:1242–1248. https://doi.org/
10.1016/j.bbi.2011.03.017
Sas AR, Bimonte-Nelson HA, Tyor WR (2007) Cognitive dysfunction in
HIV encephalitic SCID mice correlates with levels of Interferon-
alpha in the brain. AIDS 21:2151–2159. https://doi.org/10.1097/
QAD.0b013e3282f08c2f
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ:
25 years of image analysis. Nat Methods 9:671–675
Schwarz JM, Bilbo SD (2012) Sex, glia, and development: interactions in
health and disease. Horm Behav 62:243–253. https://doi.org/10.
1016/j.yhbeh.2012.02.018
Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I, Group
HIVNRC (2011) Neurocognitive consequences of HIV infection in
older adults: an evaluation of the "cortical" hypothesis. AIDS Behav
15:1187–1196. https://doi.org/10.1007/s10461-010-9815-8
Scotter EL, Abood ME, Glass M (2010) The endocannabinoid system as
a target for the treatment of neurodegenerative disease. Br J
Pharmacol 160:480–498. https://doi.org/10.1111/j.1476-5381.
2010.00735.x
Shen M, Thayer SA (1998) Cannabinoid receptor agonists protect cul-
tured rat hippocampal neurons from excitotoxicity. Mol Pharmacol
54:459–462
Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM
(2001) Striatal cannabinoid CB1 receptor mRNA expression is de-
creased in the reserpine-treated rat model of Parkinson's disease.
Exp Neurol 169:400–406. https://doi.org/10.1006/exnr.2001.7649
TangMX, Jacobs D, Stern Y,Marder K, Schofield P, Gurland B,Andrews
H, Mayeux R (1996) Effect of oestrogen during menopause on risk
and age at onset of Alzheimer's disease. Lancet 348:429–432.
https://doi.org/10.1016/S0140-6736(96)03356-9
Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke
L (1994) Central nervous system damage produced by expression of
the HIV-1 coat protein gp120 in transgenic mice. Nature 367:188–
193. https://doi.org/10.1038/367188a0
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998)
Immunohistochemical distribution of cannabinoid CB1 receptors
in the rat central nervous system. Neuroscience 83:393–411
Van den Buuse M, Low JK, Kwek P, Martin S, Gogos A (2017) Selective
enhancement of NMDA receptor-mediated locomotor hyperactivity
by male sex hormones in mice. Psychopharmacology (Berl) 234:
2727–2735. https://doi.org/10.1007/s00213-017-4668-8
Van Laere K, Goffin K, Bormans G, Casteels C, Mortelmans L, de Hoon
J, Grachev I, Vandenbulcke M, Pieters G (2009) Relationship of
type 1 cannabinoid receptor availability in the human brain to
novelty-seeking temperament. Arch Gen Psychiatry 66:196–204.
https://doi.org/10.1001/archgenpsychiatry.2008.530
Wang YQ, Pan Y, Zhu S, Wang YG, Shen ZH, Wang K (2017) Selective
impairments of alerting and executive control in HIV-infected pa-
tients: evidence from attention network test. Behav Brain Funct 13:
11. https://doi.org/10.1186/s12993-017-0129-0
Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M
(1994) Cannabinoid receptor binding and messenger RNA expres-
sion in human brain: an in vitro receptor autoradiography and in situ
hybridization histochemistry study of normal aged and Alzheimer's
brains. Neuroscience 63:637–652
Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC,
Melendez LM,Maldonado E, Zorrilla CD, Garcia H, Kraiselburd E,
Nath a (2006) Prevalence of human immunodeficiency virus-
associated cognitive impairment in a group of Hispanic women at
risk for neurological impairment. J Neurovirol 12:356–364 doi:
https://doi.org/10.1080/13550280600964576
Xu C, Hermes DJ, Mackie K, Lichtman AH, Ignatowska-Jankowska
BM, Fitting S (2016) Cannabinoids occlude the HIV-1 tat-induced
decrease in GABAergic neurotransmission in prefrontal cortex
slices. J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-
016-9664-y
Xu C, Hermes DJ, Nwanguma B, Jacobs IR, Mackie K, Mukhopadhyay
S, Lichtman AH, Ignatowska-Jankowska B, Fitting S (2017)
Endocannabinoids exert CB1 receptor-mediated neuroprotective ef-
fects in models of neuronal damage induced by HIV-1 tat protein.
Mol cell Neurosci 83:92–102. https://doi.org/10.1016/j.mcn.2017.
07.003
Yadawa AK, Chaturvedi CM (2016) Expression of stress hormones AVP
and CRH in the hypothalamus of Mus musculus following water
and food deprivation. Gen Comp Endocrinol 239:13–20. https://doi.
org/10.1016/j.ygcen.2016.03.005
Yiğit S, Mendes M (2018) Which effect size measure is appropriate for
one-way and two-way ANOVAmodels? AMonte Carlo Simulation
Study vol 16
Zhang XM, Zhu SW, Duan RS, Mohammed AH, Winblad B, Zhu J
(2008) Gender differences in susceptibility to kainic acid-induced
neurodegeneration in aged C57BL/6 mice. Neurotoxicology 29:
406–412. https://doi.org/10.1016/j.neuro.2008.01.006
Publisher’s Note Springer Nature remains neutral with regard to jurisdic
tional claims in published maps and institutional affiliations.
J Neuroimmune Pharmacol (2019) 14:661–678678
